Skip to content

A retrospective clinical study for the contribution of protein-energy wasting and inflammation in the impact of calcimimetics on survival in dialysis patients.

A retrospective clinical study for the contribution of protein-energy wasting and inflammation in the impact of calcimimetics on survival in patients on hemodialysis using dialyzers with beta2-microglobulin clearance of more than 70 mL/min and online hemodiafiltration. - Prognostic evaluation of protein-energy wasting, inflammation, and calcimimetics in patients on HD using dialyzers with beta2-microglobulin clearance of more than 70 mL/min and OHDF.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000057578
Enrollment
783
Registered
2026-03-31
Start date
2025-04-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with end-stage kidney disease undergoing hemodialysis and online hemodiafiltration

Interventions

None listed

Sponsors

Social medical corporation Kawashimakai Kawashima Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients on maintenance hemodialysis or online hemodialysis as of July 1, 2017

Exclusion criteria

Exclusion criteria: 1 Use of dialyzers with beta2-microgloburln clearance below 70 mL/min 2 Missing data for covariates at study entry 3 Dialysis conditionssuch as dialysis method and membrane material between April 1, 2017 and June 30, 2017, which are different from those as of July 1, 2017 4 Blood purification methods other than HD 5 Dialysis frequency below 3 sessions per week or dialysis time below 3 hour per session 6 Predilution online hemodiafiltration substitution volume of <60 L and postdilution online hemodiafiltration substitution volume of <8 L

Design outcomes

Primary

MeasureTime frame
2-year all-cause mortality

Countries

Japan

Contacts

Public ContactManabu Tashiro

Social medical corporation Kawashimakai Kawashima Hospital Department of Nephrology

m.tashiro@khg.or.jp08081571675

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026